List of Excipients in Branded Drug RHAPSIDO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	RHAPSIDO	remibrutinib	0078-1483	CELLULOSE, MICROCRYSTALLINE	2034-11-13
Novartis Pharmaceuticals Corporation	RHAPSIDO	remibrutinib	0078-1483	COPOVIDONE K25-31	2034-11-13
Novartis Pharmaceuticals Corporation	RHAPSIDO	remibrutinib	0078-1483	CROSCARMELLOSE SODIUM	2034-11-13
Novartis Pharmaceuticals Corporation	RHAPSIDO	remibrutinib	0078-1483	FERRIC OXIDE RED	2034-11-13
Novartis Pharmaceuticals Corporation	RHAPSIDO	remibrutinib	0078-1483	FERRIC OXIDE YELLOW	2034-11-13

Rhapsido (Remibrutinib) Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Rhapsido is the proposed brand for remibrutinib, an oral, covalent Bruton’s tyrosine kinase inhibitor developed by Novartis for chronic spontaneous urticaria and related allergic diseases. The commercial formulation opportunity is likely a small, immediate-release tablet optimized for rapid systemic exposure, chemical stability, high-dose manufacturing efficiency, and global supply-chain flexibility. The strongest excipient-related opportunities are not conventional “me-too” tablets, but differentiated low-moisture formulations, alternative manufacturing processes, pediatric presentations, and lifecycle products that reduce administration burden.

What is Rhapsido and what formulation is commercially relevant?

Rhapsido refers to remibrutinib, also known as LOU064. Remibrutinib is an orally administered small molecule designed to inhibit BTK signaling in mast cells and basophils. Its primary commercial use is expected to be chronic spontaneous urticaria in patients inadequately controlled by antihistamines, with potential expansion into other allergic and inflammatory indications.

Attribute	Commercial assessment
Active ingredient	Remibrutinib
Development code	LOU064
Drug class	Covalent BTK inhibitor
Primary target	Bruton’s tyrosine kinase
Initial disease area	Chronic spontaneous urticaria
Likely dosage form	Oral immediate-release tablet
Expected administration	Twice-daily dosing in late-stage development
Originator	Novartis
Primary formulation opportunity	Stable, scalable immediate-release solid oral dosage form
Secondary opportunities	Pediatric liquid, orally disintegrating tablet, dose-flexible tablet, regional formulation variants

Phase 3 studies evaluated remibrutinib in chronic spontaneous urticaria, including patients who remained symptomatic despite H1-antihistamine treatment. The development program included the REMIX-1 and REMIX-2 studies, which reported clinically meaningful reductions in urticaria activity and itch scores.[1][2]

The commercial formulation must support chronic use. That requirement favors low tablet burden, consistent dissolution, low moisture uptake, and robust tabletability over elaborate modified-release technology.

What excipient strategy is most suitable for Rhapsido?

A conventional immediate-release formulation is the most commercially rational starting point. The active pharmaceutical ingredient should be incorporated into a direct-compression or dry-granulated tablet if powder-flow, content-uniformity, and compactibility data permit.

Recommended excipient architecture

Formulation function	Preferred excipient classes	Commercial rationale
Diluent	Microcrystalline cellulose, mannitol, lactose alternative, dibasic calcium phosphate	Controls tablet size and improves manufacturability
Binder	Copovidone, povidone, hydroxypropyl cellulose	Supports compact strength at low drug load
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and sticking
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or approved colorants	Improves swallowability, identification, and moisture protection
Antioxidant or stabilizer	Product-specific and data-dependent	May be required if the API is oxidation-sensitive

The preferred platform would use a low number of excipients with established global regulatory histories. This reduces supplier qualification, reduces elemental-impurity and nitrosamine assessment burden, and simplifies registration across the United States, European Union, Japan, and emerging markets.

Direct compression versus wet granulation

Direct compression offers the lowest processing cost and the shortest manufacturing route. It also reduces exposure to water and heat, which may be important if remibrutinib is sensitive to hydrolysis or solid-state conversion.

Dry granulation is a stronger fallback when the API has poor flow, segregation risk, or insufficient compactibility. Roller compaction allows the manufacturer to improve bulk density without adding water. It can also provide a defensible process patent position if the process materially improves dissolution, assay uniformity, or stability.

Wet granulation should be used only where the product requires it. It adds drying, solvent or water exposure, energy consumption, and process controls. A wet-granulated product may be commercially appropriate if it provides a meaningful improvement in content uniformity or tablet robustness, but it is less attractive as a default strategy.

What excipient risks could affect remibrutinib product development?

The most relevant risks are chemical instability, solid-state variability, poor content uniformity, and excipient-driven dissolution changes.

Chemical stability

Remibrutinib is a covalent kinase inhibitor. The molecule’s electrophilic warhead and heterocyclic structure may create sensitivity to moisture, pH, nucleophilic excipients, or oxidative conditions. The formulation program should evaluate:

• Water activity and residual moisture.
• Exposure to alkaline and acidic microenvironments.
• Peroxide levels in povidone, crospovidone, and polyethylene glycol.
• Reactive impurities in excipients.
• Packaging moisture ingress.
• Formation of degradants during accelerated stability.
• Compatibility with printing inks, adhesives, and coating systems.

Excipient selection should avoid assuming that compendial compliance establishes compatibility. Low-peroxide grades and tightly controlled moisture specifications may be commercially preferable even where they increase raw-material cost.

Solid-state and particle-size control

If remibrutinib has multiple polymorphs, hydrates, or amorphous fractions, excipients and processing conditions can affect physical stability. Milling energy, compaction pressure, granulation, and storage humidity should be evaluated for changes in:

• Polymorphic form.
• Amorphous content.
• Particle-size distribution.
• Dissolution profile.
• Tablet tensile strength.
• Disintegration time.

A formulation that protects the selected solid form can support a stronger composition-of-matter extension strategy than a simple excipient substitution.

Content uniformity

If the commercial tablet contains a relatively low mass of remibrutinib, segregation risk becomes important. Ordered mixing, carrier selection, particle-size matching, and low-shear blending may be required. Microcrystalline cellulose and spray-dried lactose are common solutions, but lactose-free alternatives may have commercial value for global markets and sensitive patient populations.

What formulation patents could protect Rhapsido?

The basic tablet composition is unlikely to provide the strongest long-term protection unless it contains a narrow excipient combination linked to an unexpected technical effect. More valuable claims may cover the following technical features:

1. A stable remibrutinib solid oral dosage form with specified impurity limits.
2. A formulation with controlled moisture activity.
3. A tablet made by direct compression using defined particle-size distributions.
4. A dry-granulated product with improved content uniformity.
5. A formulation that preserves a specific polymorph or amorphous-solid dispersion.
6. A low-dose tablet with rapid dissolution and reduced food effect.
7. A formulation with specified dissolution at acidic and neutral pH.
8. A moisture-protective coating and high-barrier packaging combination.
9. A pediatric liquid or multiparticulate formulation.
10. A tablet or capsule that avoids reactive excipients or peroxide-mediated degradation.

Patent-strength assessment

Claim type	Expected strength	Commercial value
Broad “remibrutinib plus tablet excipients” claim	Low	Limited blocking power
Narrow excipient ratio claim	Low to moderate	Useful if tied to reproducible performance
Stability claim with defined degradant limits	Moderate	Can delay substitution if difficult to design around
Process claim for dry granulation or compression	Moderate	Protects manufacturing route, not all products
Polymorph or solid-form claim	Moderate to strong	Often more valuable than excipient claims
Pediatric liquid formulation	Moderate	Supports lifecycle exclusivity
ODT or dose-flexible formulation	Moderate	Enables differentiation and new-market access
Packaging and moisture-control claim	Moderate	Protects product quality, subject to design-around risk

Under United States patent law, an excipient patent must generally demonstrate novelty and non-obviousness. A claim that simply combines familiar fillers, binders, and disintegrants may face substantial obviousness risk. The prosecution record should therefore emphasize measured technical effects, such as improved stability, reduced food effect, or a dissolution profile that cannot be predicted from routine formulation work.

What commercial opportunities exist beyond the initial Rhapsido tablet?

The greatest commercial opportunities are linked to patient segmentation, administration burden, and geographic expansion.

Pediatric formulation

Chronic urticaria affects children, and pediatric development can support a separate product strategy. Potential dosage forms include:

• Oral solution.
• Powder for reconstitution.
• Mini-tablet.
• Orally disintegrating tablet.
• Multiparticulate sachet.

A liquid product would require preservatives, pH adjustment, taste masking, viscosity control, microbial protection, and container-closure compatibility. A powder-for-reconstitution product could reduce chemical degradation during storage but would transfer complexity to dispensing and reconstitution.

A mini-tablet may offer the best balance between dose accuracy, stability, and manufacturing simplicity. It can also reduce the preservative and taste-masking burden of a liquid.

Orally disintegrating tablet

An ODT could improve administration for patients with difficulty swallowing, although the commercial benefit depends on whether the target population has a meaningful need for that feature. Excipients would likely include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and a taste-masking system.

The technical risk is taste. A potent kinase inhibitor can create a strong bitter profile even at low dose. Coating, ion-exchange resins, lipid barriers, and polymeric taste-masking systems may be required. Each added excipient increases formulation complexity and may slow disintegration.

Dose-flexible presentation

A 10 mg, 25 mg, or scored tablet strategy could support dose adjustment, pediatric use, hepatic or renal impairment populations, and market-specific prescribing practices. Dose flexibility can also reduce inventory complexity if one tablet strength can cover multiple regimens.

Combination therapy

Rhapsido may be used alongside antihistamines or other allergy therapies. A fixed-dose combination would face regulatory and clinical hurdles, but a co-pack strategy could be commercially simpler. A combination tablet would require compatibility studies, separate dissolution controls, and justification of the combined clinical benefit.

Emerging-market products

Lower-cost markets may favor:

• Uncoated tablets.
• Blister packs rather than bottles.
• Lactose-free excipient systems.
• Localized film-coating colors.
• High-throughput dry granulation.
• Fewer tablet strengths.

The same core formulation should be adaptable across markets to avoid separate stability programs and manufacturing lines.

How does Rhapsido compare with competing allergic-disease products?

Rhapsido competes with biologic and oral therapies rather than with BTK inhibitors alone. The principal commercial comparators include omalizumab, dupilumab in relevant indications, antihistamines, and other emerging oral mast-cell or immunologic agents.

Product or class	Route	Main formulation burden	Commercial implication
Remibrutinib/Rhapsido	Oral	Tablet stability, adherence, chronic exposure	Lower administration burden than injectable biologics
Omalizumab	Subcutaneous injection	Biologic stability and cold chain	Higher administration burden but established efficacy
Dupilumab	Subcutaneous injection	Biologic delivery and injection training	Strong specialty-pharmacy positioning
H1 antihistamines	Oral	Low-cost tablets or liquids	Price pressure and broad availability
Other oral targeted agents	Oral	Similar solid-dose manufacturing challenges	Differentiation depends on efficacy, safety, and dosing

An oral product can capture patients who prefer to avoid injections and may reduce clinic administration costs. Excipient strategy should support this commercial position by prioritizing small tablets, rapid disintegration, low pill burden, and room-temperature stability where supported by data.

What FDA regulatory issues apply to Rhapsido excipients?

FDA approval of the final product will depend on the complete formulation, manufacturing process, specifications, stability data, and clinical bridging requirements. Excipient selection must address:

• Inactive Ingredient Database status.
• Maximum daily exposure.
• Route-specific precedent.
• Residual solvents.
• Elemental impurities under ICH Q3D.
• Nitrosamine risk.
• Peroxide and reactive impurity controls.
• Microbial limits.
• Container-closure compatibility.
• Global regulatory acceptability.

A new excipient or unusually high level of an established excipient could trigger additional toxicology and regulatory review. The lowest-risk approach is to use excipients with oral immediate-release precedent at comparable exposure levels.

FDA’s product-specific expectations would be reflected in the approved prescribing information, Chemistry, Manufacturing, and Controls review, and any public regulatory documents. Novartis would also need to establish a validated control strategy for degradants linked to the API, excipients, manufacturing equipment, and packaging.[3][4]

What manufacturing and intellectual-property barriers could affect generic entry?

Generic entry would likely face fewer barriers from the excipient list than from active-ingredient patents, solid-form patents, process patents, and clinical-use claims. The formulation can often be designed around common excipients unless the originator has demonstrated a narrow and technically necessary composition.

Important barriers include:

• Remibrutinib active-ingredient patent term.
• Solid-form and polymorph patents.
• Crystalline salt or solvate patents.
• Manufacturing-process patents.
• Tablet composition patents.
• Method-of-use patents for chronic spontaneous urticaria.
• Pediatric or additional-indication patents.
• Regulatory exclusivity.
• Difficulty matching dissolution across pH conditions.
• Proprietary impurity-control methods.

A generic applicant may pursue a Paragraph IV certification against listed patents in the United States. The commercial effect would depend on the number of Orange Book-listed patents, litigation timing, settlement terms, and the strength of the generic applicant’s invalidity and non-infringement positions.

Excipient patents alone are unlikely to prevent a determined generic launch if the generic can use a different diluent, binder, disintegrant, or manufacturing process while meeting bioequivalence and quality requirements.

What licensing opportunities exist in Rhapsido formulation technology?

Potential licensing targets include:

• Low-peroxide excipient platforms.
• Moisture-barrier coating systems.
• Amorphous-solid-dispersion technology.
• Pediatric taste-masking systems.
• Mini-tablet manufacturing platforms.
• Continuous direct-compression systems.
• High-throughput dry granulation.
• Novel ODT technologies.
• Packaging systems with validated low moisture ingress.

The most attractive licensing transaction would attach a measurable product advantage to the technology. Examples include longer shelf life, fewer cold-chain requirements, reduced tablet size, improved dissolution, lower manufacturing cost, or a clinically useful pediatric presentation.

A generic excipient vendor’s broad platform patent is less valuable than a formulation package with development data, scale-up evidence, regulatory precedent, and freedom-to-operate analysis.

How strong is the commercial excipient opportunity for Rhapsido?

The opportunity is moderate for the initial tablet and stronger for lifecycle products.

Opportunity	Commercial attractiveness	Patent attractiveness	Development risk
Standard immediate-release tablet	High	Low to moderate	Low
Lactose-free tablet	Moderate	Low	Low
Moisture-protective formulation	High if stability improves	Moderate	Moderate
Direct-compression platform	High	Moderate	Moderate
Pediatric mini-tablet	High	Moderate	Moderate
Oral solution	Moderate	Moderate	High
ODT	Moderate	Moderate	High
Fixed-dose combination	Uncertain	Moderate	High
Amorphous-solid-dispersion formulation	High if needed	Moderate to strong	High

The commercial priority should be a robust immediate-release tablet, followed by pediatric and administration-friendly products. A complex formulation should not be pursued unless the API’s physicochemical properties create a clear need.

Key Takeaways

• Rhapsido is associated with remibrutinib, an oral covalent BTK inhibitor developed by Novartis.
• The initial commercial product is most likely to rely on a conventional immediate-release tablet.
• Direct compression or dry granulation should be prioritized over wet granulation where stability and powder properties allow.
• The main formulation risks are moisture sensitivity, oxidative degradation, solid-state variability, content uniformity, and dissolution control.
• Broad excipient claims are vulnerable to design-around and obviousness challenges.
• Stronger formulation protection may come from stability-linked compositions, solid forms, particle-size controls, and manufacturing processes.
• Pediatric mini-tablets, oral liquids, and ODTs offer the clearest lifecycle opportunities.
• Generic risk will depend more heavily on active-ingredient, solid-form, process, and method-of-use patents than on standard excipient selections.
• Low-moisture excipient systems and high-barrier packaging could provide both product-quality and patent value.
• The best licensing targets are technologies supported by scale-up data and a measurable performance advantage.

FAQs

Can an excipient patent block generic remibrutinib?

Usually not by itself. A generic manufacturer may avoid infringement by selecting a different diluent, binder, disintegrant, coating, or manufacturing process, provided the product meets regulatory requirements.

Would Rhapsido benefit from a lactose-free formulation?

Potentially. A lactose-free formulation could simplify global commercialization and reduce dependence on a single diluent system, but it would need comparable tabletability, stability, dissolution, and cost performance.

Is a remibrutinib oral solution commercially attractive?

It could support pediatric use, but the formulation would face taste-masking, preservative, microbial, pH, packaging, and chemical-stability challenges. A mini-tablet may offer a lower-risk pediatric alternative.

Could an Rhapsido ODT command premium pricing?

Only if it provides a clear patient or caregiver benefit. The commercial case would depend on swallowing difficulty, adherence, taste performance, tablet robustness, and whether payers recognize value beyond the standard tablet.

Which formulation technology is most likely to create durable value?

A technology that improves chemical stability, shelf life, dissolution consistency, or pediatric dosing is more likely to create durable value than a routine excipient substitution.

References

1. Novartis. (2024). Novartis remibrutinib phase III data demonstrate rapid and sustained efficacy in chronic spontaneous urticaria. Novartis investor and corporate communications.

2. ClinicalTrials.gov. (n.d.). REMIX-1 and REMIX-2 studies of remibrutinib in chronic spontaneous urticaria. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2019). Inactive ingredient database. Center for Drug Evaluation and Research.

4. International Council for Harmonisation. (2022). ICH Q3D(R2): Guideline for elemental impurities. ICH.